Progyny, Inc. Stock Price, News & Analysis

Progyny, Inc. (Nasdaq: PGNY), a leader in fertility benefits management, announced its participation in the Credit Suisse 31st Annual Healthcare Conference. CEO Pete Anevski and CFO Mark Livingston will engage in a fireside chat on November 8, 2022, at 4:25 PM PT (7:25 PM ET). A live audiocast will be available on Progyny's website. The company is committed to enhancing family building benefits, providing patients with education and access to leading fertility specialists, ultimately reducing healthcare costs and improving clinical outcomes.

Progyny, Inc. (Nasdaq: PGNY) reported record quarterly revenue of $205.4 million, a 68% increase year-over-year, for the third quarter of 2022. The company secured a record 105 new client commitments, adding approximately 1.2 million covered lives. Adjusted EBITDA more than doubled to $35.0 million, reflecting strong demand for fertility solutions. However, net income decreased 21% to $13.2 million due to increased non-cash stock-based compensation. Full-year revenue guidance was raised to between $775 million and $785 million, indicating continued growth.

Progyny, Inc. (Nasdaq: PGNY) will report its financial results for Q3 2022 on November 3, 2022, after market close. A conference call will follow at 4:45 P.M. ET, accessible via dialing 1-866-825-7331 (U.S.) or 1-973-413-6106 (international) with passcode 265484. An audio replay will be available until November 10, 2022. Progyny specializes in fertility benefits management, aiming to improve patient outcomes and reduce employer costs. The company has received multiple accolades, including recognition from CNBC Disruptor 50 and Modern Healthcare.

Progyny (Nasdaq: PGNY), a leader in fertility benefits management, announced that CEO Pete Anevski and CFO Mark Livingston will join a fireside chat at the BofA Securities 2022 Global Healthcare Conference on September 15, 2022, at 5:50 A.M. Eastern Time. This event aims to discuss Progyny's comprehensive fertility solutions which benefit employers, patients, and healthcare providers. Interested parties can access a live audiocast and replay on Progyny's website. The company has received multiple awards for its innovative approach to fertility benefits.

Progyny (Nasdaq: PGNY) announced the appointment of Lloyd Dean to its Board of Directors, effective August 30, 2022. Dean, the Chief Executive Emeritus of CommonSpirit Health, brings over 40 years of healthcare experience. Progyny's CEO, Pete Anevski, expressed confidence that Dean's expertise will enhance the company’s growth and leadership in fertility and family building benefits. Following this appointment, the Board now consists of ten members. Dean will serve on the Nominating and Corporate Governance Committee, focusing on expanding access to fertility solutions.

Progyny, Inc. (PGNY) reported record quarterly revenue of $195.0 million, reflecting a 52% growth from the prior year. Strong demand for fertility benefits led to a 37% increase in fertility services revenue, totaling $126.8 million, and an 87% surge in pharmacy services revenue, reaching $68.2 million. Despite a 53% decrease in net income, attributed to increased stock-based compensation, Adjusted EBITDA saw a 78% increase, reaching $32.9 million. The company raised its full-year guidance, projecting annual revenue between $750.0 million and $775.0 million.

Progyny's Clinical Outcomes Exceed National Benchmarks

Progyny (Nasdaq: PGNY), a leader in fertility benefits management, has achieved superior clinical outcomes validated by Milliman, Inc. Its independent evaluation confirms Progyny’s methodology for measuring and publishing fertility treatment successes against national benchmarks. Since 2016, Progyny has consistently delivered faster pregnancies, fewer miscarriages, and healthier outcomes compared to national averages. The company emphasizes transparency and aims to raise standards in fertility benefits as it continues to expand its network of high-quality providers.

Progyny (PGNY) will release its financial results for Q2 2022 on August 4, 2022, after market close. An investor conference call is scheduled for 4:45 PM ET. Participants in the U.S. can join by dialing 1-866-825-7331, with international access via 1-973-413-6106, using passcode 265484. A replay will be available until August 11, 2022. Progyny, recognized for its comprehensive fertility benefits, aims to provide optimal clinical outcomes and reduce healthcare costs.

Progyny, a leader in fertility and family building benefits, will have its CEO Pete Anevski and CFO Mark Livingston engage in a fireside chat at the Jefferies 2022 Healthcare Conference on June 8, 2022, at 10:30 A.M. Eastern Time. This event will be accessible via a live audiocast on Progyny’s website. The company’s innovative solutions are designed to empower patients and reduce healthcare costs for employers while achieving optimal clinical outcomes. Progyny is headquartered in New York City and has received numerous recognitions for its growth and leadership in the healthcare sector.